Clinical Trials · NCT07574723
Tirzepatide Titration to Reduce Side Effects in Individuals With Obesity
- Phase
- N/A
- Recruitment status
- Recruiting
- Sponsor
- Dasman Diabetes Institute
- Enrollment
- 68
- Start date
- May 2026
- Locations
- 1 site, Kuwait
- Primary endpoint
- Vomiting episodes per patient assessed using the Modified Index of Nausea, Vomiting, and Retching (M-INVR)